Gastroenterology

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Source link

Related posts

Emricasan reduces portal pressure in cirrhosis despite missing endpoint

Newsemia

Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis

Newsemia

Elevated fecal calprotectin predicts Crohn’s progression

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World